OverviewSuggest Edit

Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential. The company is headquartered in Cambridge, MA.
TypePublic
Founded2014
HQCambridge, US
Websiteunumrx.com

Latest Updates

Employees (est.) (Apr 2018)56(-3%)
Revenue (FY, 2017)$8.4 M(+32%)
Share Price (Aug 2020)$2.6 (-3%)
Cybersecurity ratingAMore

UNUM Therapeutics Office Locations

UNUM Therapeutics has an office in Cambridge
Cambridge, US (HQ)
200 Cambridgepark Dr #3100
Show all (1)

UNUM Therapeutics Financials and Metrics

UNUM Therapeutics Revenue

UNUM Therapeutics's revenue was reported to be $8.36 m in FY, 2017 which is a 31.5% increase from the previous period.
USD

Revenue (FY, 2017)

8.4m

Revenue growth (FY, 2016 - FY, 2017), %

31.5%

Net income (FY, 2017)

(25.5m)

EBIT (FY, 2017)

(26.2m)

Market capitalization (6-Aug-2020)

82.3m

Closing stock price (6-Aug-2020)

2.6

Cash (31-Dec-2017)

28.3m
UNUM Therapeutics's current market capitalization is $82.3 m.
USDFY, 2015FY, 2016FY, 2017

Revenue

3.0m6.4m8.4m

Revenue growth, %

113%32%

General and administrative expense

2.7m3.4m4.7m

R&D expense

6.9m22.0m29.8m
USDFY, 2016FY, 2017

Cash

41.3m28.3m

Accounts Receivable

928.0k830.0k

Prepaid Expenses

296.0k513.0k

Current Assets

69.7m42.4m
USDFY, 2015FY, 2016FY, 2017

Net Income

(6.6m)(18.1m)(25.5m)

Depreciation and Amortization

179.0k830.0k1.2m

Accounts Payable

705.0k389.0k(31.0k)

Cash From Operating Activities

17.7m(18.6m)(25.8m)
Show all financial metrics

UNUM Therapeutics Operating Metrics

Mar, 2018

Phase I Trials Products

3

Pre-Clinical Phase Products

1
Show all operating metrics

UNUM Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

UNUM Therapeutics Online and Social Media Presence

Embed Graph

UNUM Therapeutics News and Updates

Thinking about buying stock in Unum Therapeutics, Nokia, Amneal Pharmaceuticals, Aytu Bioscience, or Niu Technologies?

NEW YORK, July 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UMRX, NOK, AMRX, AYTU, and NIU. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Unum Therapeutics, Diffusion Pharmaceuticals, Sunrun Inc, Delta Air Lines, or Hertz Global Holdings?

NEW YORK, July 7, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UMRX, DFFN, RUN, DAL, and HTZ. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Unum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Updates

CAMBRIDGE, Mass., March 26, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided corpo…

Unum Therapeutics Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital

CAMBRIDGE, Mass., March 20, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced it has entered into a common stock purchase agreement for up to $25 million with Lincoln Park Capi…

Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers

-Cohort 1 enrollment is complete with no dose-limiting toxicities observed-

Unum Therapeutics Announces New Data at the American Society of Hematology (ASH) Annual Meeting

-Clinical response and safety data with ACTR707 provide proof-of-mechanism for the ACTR platform and support the ongoing Phase 1 dose-escalation trial in relapsed or refractory NHL- -Clinical response and safety data with ACTR707 provide proof-of-mechanism for the ACTR platform and support the ongoi…
Show more

UNUM Therapeutics Blogs

Unum Therapeutics to Present at the Wedbush PacGrow Healthcare Conference

Unum Therapeutics to Present at the Wedbush PacGrow Healthcare Conference Content Import Wed, 07/17/2019 - 09:01 Unum Therapeutics to Present at the Wedbush PacGrow Healthcare Conference July 17, 2019 at 9:00 AM EDT This release is a backfill from a News Wire …

Unum Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast on March 28, 2019 at 8:00 A.M. ET

CAMBRIDGE, Mass. , March 21, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer using its novel T cell technology platforms, today announced that the company will host a

Unum Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference 2019

CAMBRIDGE, Mass. , March 05, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based on its novel T cell technology platforms, today announced that Charles Wilson , Chief

Unum Therapeutics Announces Transition of Chief Financial Officer

CAMBRIDGE, Mass. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular immunotherapies, today announced that Christiana Stamoulis , President and Chief Financial Officer, will be stepping

Unum Therapeutics Announces 2019 Goals and Expected Milestones

- Multiple Data Readouts from ATTCK-20-03 and ATTCK-17-01 Expected in 2019 - - Initial Data on ATTCK-34-01, Unum’s First Program in Solid Tumors, Expected in Second Half of 2019 - - First Development Candidate from BOXR Platform Advancing Toward Clinical Development - CAMBRIDGE, Mass. , Jan.

Unum Therapeutics Added to NASDAQ Biotechnology Index

CAMBRIDGE, Mass. , Dec. 20, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular immunotherapies, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI),
Show more

UNUM Therapeutics Frequently Asked Questions

  • When was UNUM Therapeutics founded?

    UNUM Therapeutics was founded in 2014.

  • How many employees does UNUM Therapeutics have?

    UNUM Therapeutics has 56 employees.

  • What is UNUM Therapeutics revenue?

    Latest UNUM Therapeutics annual revenue is $8.4 m.

  • What is UNUM Therapeutics revenue per employee?

    Latest UNUM Therapeutics revenue per employee is $149.3 k.

  • Who are UNUM Therapeutics competitors?

    Competitors of UNUM Therapeutics include Artios Pharma, NovellusDx and Microskin.

  • Where is UNUM Therapeutics headquarters?

    UNUM Therapeutics headquarters is located at 200 Cambridgepark Dr #3100, Cambridge.

  • Where are UNUM Therapeutics offices?

    UNUM Therapeutics has an office in Cambridge.

  • How many offices does UNUM Therapeutics have?

    UNUM Therapeutics has 1 office.